Study used blood test to identify distinct molecular signatures of disease; paves the way to precision medicine for cystic fibrosis
Researchers at Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago, and colleagues, used a blood test and microarray technology to identify distinct molecular signatures in children with cystic fibrosis. These patterns of gene expression ultimately could help predict disease severity and treatment response, and lead to therapies tailored to each patient’s precise biology. Findings were published in Physiological Genomics.
“Our findings pave the way to precision medicine for cystic fibrosis patients, eventually helping us match treatment to each patient’s unique genomic pattern of disease,” says lead author Hara Levy, MD, MMSc, from Manne Research Institute at Lurie Children’s, who is an Associate Professor of Pediatrics at Northwestern University Feinberg School of Medicine. “Our study was the first to identify molecular signatures of cystic fibrosis from a blood test taken during a routine clinic visit, giving us a baseline. Greater understanding of these molecular signatures may lead to unique molecular markers that could help us intervene earlier to changes in a patient’s inflammatory response to airway infection or pancreatic function, allowing us to provide more focused treatment. It would be a huge improvement over the one-size-fits-all treatment approach we currently have for patients with cystic fibrosis.”
To identify baseline molecular signatures in cystic fibrosis, Dr. Levy’s lab obtained genomic information from patients’ blood samples using cutting-edge technologies such as Affymetric array and Illumina MiSeq. The team then merged this genomic information with each individual’s clinical history gathered from electronic medical records. They compared this snapshot of patient-specific data with healthy controls. Their study provides strong evidence for distinct molecular signatures in cystic fibrosis patients that correlate with clinical outcomes.
Cystic fibrosis is a progressive genetic disease that damages multiple organs, including the lungs and pancreas. Currently, the average predicted survival is 47 years. Although cystic fibrosis is caused by dysfunction of a single gene (CFTR) and treatment that targets CFTR mutations is available, the relationships between the abnormal gene product, development of inflammation and disease progression are not fully understood. This limits the ability to predict a patient’s clinical course, provide individualized treatment and rapidly monitor treatment response.
For example, it is not clear why patients with cystic fibrosis are susceptible to chronic lung infections, since they are considered to have a functional immune system.
“We are now trying to discover why patients with cystic fibrosis become infected so easily,” says Dr. Levy. “We are taking a closer look at the immune cells that make up many of the molecular signatures we found in cystic fibrosis.”
More study is needed before precision medicine for cystic fibrosis reaches the clinic.
“With more research, a blood test to gather genomic specifics of each patient’s disease might be available in the clinic within the next five years,” says Dr. Levy. “Precision medicine will revolutionize care for cystic fibrosis patients.”
The Latest on: Cystic fibrosis
[google_news title=”” keyword=”cystic fibrosis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cystic fibrosis
- Lipid nanoparticles research closing in on genetic treatments for hereditary lung disease, vision losson March 4, 2024 at 2:18 pm
Researchers who work with tiny drug carriers known as lipid nanoparticles have developed a new type of material capable of reaching the lungs and the eyes, an important step toward genetic therapy for ...
- Cellectric and Resistell Collaborate to Improve Cystic Fibrosis Therapieson March 3, 2024 at 4:00 pm
Cellectric and Resistell began a collaborative project which will focus on the development of a workflow aimed at accelerating the pace at which cystic fibrosis patients receive targeted antibiotic ...
- Non-profit raises awareness for cystic fibrosis with womanless pageanton March 2, 2024 at 6:40 am
SUFFOLK, Va. — A Hampton Roads mother and a non-profit foundation are raising awareness for cystic fibrosis after she lost her daughter to the debilitating disease. "Martina was the life of every ...
- Bonhill cystic fibrosis charity given funding boost by Dumbarton McDonald'son March 1, 2024 at 6:20 am
A Bonhill charity chief says a funding boost from McDonald’s in Dumbarton will help change lives. Flutterby FUNdraisers for Cystic Fibrosis were awarded £3000 by the fast food giant, with the money ...
- Legally blind Big Brother star Reggie Bird opens up about her debilitating illness and her son's cystic fibrosison February 29, 2024 at 5:37 am
The 49-year-old, who is legally blind, took to Instagram on Thursday to tell followers she will tackle take every day 'as it comes' as she supports her son Lucas's struggle with cystic fibrosis.
- What we've found out about cystic fibrosis patients and dieton February 28, 2024 at 6:55 am
New research indicates that quality as well as quantity matters when it comes to what people with cystic fibrosis eat ...
- Cystic fibrosis breakthrough points to zinc as infection busteron February 26, 2024 at 12:15 am
Zinc has been found to be important in keeping lung infections at bay in people with cystic fibrosis, whose immune cell’s natural bacteria-fighting ability has been reduced by the genetic mutation ...
- Living with cystic fibrosis: Bradley thought his life was over at 18. He penned his own eulogy. Then, he defied oddson February 23, 2024 at 4:12 am
Bradley Dryburgh thought his life was over before it had truly begun. The 27-year-old, from Wollongong, has been living with cystic fibrosis (CF) all his life — having been diagnosed with the ...
- Vertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Olderon February 23, 2024 at 4:11 am
If approved, KALYDECO ® will be the first and only medicine approved in Europe to treat the underlying cause of cystic fibrosis in babies as young as 1 month with specific mutations in the CFTR gene - ...
- Cystic fibrosis patient, 26, receives 3rd set of lungs after begging doc to take her case: ‘I was always told that two was it’on February 22, 2024 at 6:44 pm
Taylor Stephenson, 26, received her third set of lungs on Jan. 13 at Duke Hospital University after going into rejection in April.
via Bing News